

## DAFTAR PUSTAKA

- Afrifa, J., Gyekye, S.A., Owiredo, W.K., Ephraim, R.K., Baidoo, S.E., Amoah, S., 2015, Application of sigma metrics for the assessment of quality control in clinical chemistry laboratory in Ghana: A pilot study, *Niger Med J.*, 56, 1, 54–58.
- Alcorta, I., Pereira, A., Ordinas, A., 1996, Clinical and laboratory factors associated with platelet transfusion refractoriness: A case-control study, *Br J Haematol*, 93, 1, 220–224.
- Ali, S.S., Tarawah, A.M., Al-Hawsawi, Z.M., Zolaly, M.A., Turkustani, W., 2015, Comprehensive patient care improves quality of life in transfusion dependent patients with  $\beta$ -thalassemia, *Saudi Med J*, 36, 5, 575–579.
- Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., *et al.*, 2016, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, *Blood*, 127, 20, 2391–2405.
- Arun, R., Yashovardhan, A., Deepthi, K., Suresh, B., Sreedhar Babu, K.V., Jothibai, D.S., 2013, Donor demographic and laboratory predictors of single donor platelet yield, *J Clin Sci Res*, 2, 4, 211–215.
- Athale, U. & Chan, A., 2007, Hemorrhagic complications in pediatric hematologic malignancies, *Semin Thromb Hemost*, 33, 4, 408–415.
- Balitsky, A.K., Liu, Y., Van der Meer, P.F., Heddle, N.M., Arnold, D.M., 2021, Exploring the components of bleeding outcomes in transfusion trials for patients with hematologic malignancy., *Transfusion*, 61, 1, 286–293.
- BCSH, 2003, British committee for standards in haematology: guidelines for the use of platelet transfusions, *Br J Haematol*, 122, 1, 10–23.
- Bishop, J.F., Matthews, J.P., Yuen, K., McGrath, K., Wolf, M.M., Szer, J., 1992, The definition of refractoriness to platelet transfusions, *Transfusion Medicine*, 2, 1, 35–41.
- Brecher, M.E., 2005, *AABB Technical Manual*, 15th ed, AABB, Maryland.
- Briggs, C., Harrison, P., Machin, S.J., 2007, Continuing developments with the automated platelet count, *Int Jnl Lab Hem*, 29, 2, 77–91.
- Brubaker, D.B., Marcus, C., Holmes, E., 1998, Intravascular and total body platelet equilibrium in healthy volunteers and in thrombocytopenic patients transfused with single donor platelets, *Am J Hematol*, 58, 3, 165–176.
- Castaman, G. & Pieri, L., 2018, Management of thrombocytopenia in cancer, *Thromb Res*, 164, January, S89–S93.
- Chapman, J., Goyal, A., Azevedo, A., 2021, *Splenomegaly*. In: *StatPearls*, T. I. (FL), StatPearls Publishing.
- CLSI, 2014, *User Verification of Precision and Estimation of Bias; Approved Guideline.*, 3rd ed., Clinical and Laboratory Standards Institute.

- Cohen, J., 1960, A Coefficient of Agreement for Nominal Scales, *Educational and Psychological Measurement*, 20, 1, 37–46.
- Cohn, C.S., 2020, Platelet transfusion refractoriness: How do I diagnose and manage?, *Hematology Am Soc Hematol Educ Program*, 20, 1, 527–532.
- Crawford, J., Dale, D.C., Lyman, G.H., 2004, Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management, *Cancer*, 100, 2, 228–237.
- Dahlan, M.S., 2010, *Besar Sampel dan Cara Pengambilan Sampel*, 3rd ed, Salemba Medika, Jakarta.
- Davis, K.B., Slichter, S., Corash, L., 1999, Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: Problems and a solution, *Transfusion*, 39, 6, 586–592.
- Dawson, B. & Trapp, R., 2004, *Basic and Clinical Biostatistics*, 4th ed, Lange Medical Books, New York.
- Delaflor-Weiss, E. & Mintz, P.D., 2000, The evaluation and management of platelet refractoriness and alloimmunization, *Transfus Med Rev*, 14, 2, 180–196.
- Doughty, H.A., Woolley, T., Thomas, G.O.R., 2011, Massive transfusion, *J R Army Med Corps*, 157, 3.
- Enein, A.A., Hussein, E.A.W., El Shafie, S., Hallouda, M., 2007, Factors affecting platelet yield and their impact on the platelet increment of patients receiving single donor PLT transfusion, *J Clin Apher*, 22, 1, 5–9.
- Enright, H., Davis, K., Gernsheimer, T., McCullough, J.J., Woodson, R., 2003, Factors influencing moderate to severe reactions to PLT transfusions : experience of the TRAP multicenter clinical trial, *Transfusion*, 43, October, 1545–1552.
- Estcourt, L.J., Birchall, J., Allard, S., Bassey, S.J., Hersey, P., Kerr, J.P., *et al.*, 2017, Guidelines for the use of platelet transfusions, *Br J Haematol*, 176, 3, 365–394.
- Ezidiegwu, C.N., Lauenstein, K.J., Rosales, L.C., Kelly, K.C., Henry, J.B., 2004, Febrile nonhemolytic transfusion reactions: Management by premedication and cost implications in adult patients, *Archives of Pathology and Laboratory Medicine*, 128, 9, 991–995.
- Flint, B. & Hall, C., 2022, *Body Surface Area*. In: *StatPearls*, StatPearls Publishing.
- Franchini, M., Frattini, F., Crestani, S., Bonfanti, C., 2013, Bleeding complications in patients with hematologic malignancies, *Semin Thromb Hemost*, 39, 1, 94–100.
- Gandasoebroto, R., 2001, *Penuntun Laboratorium Klinik*, 10th ed, Dian Rakyat, Jakarta.
- Gauer, R.L. & Braun, M.M., 2012, Thrombocytopenia., *American family physician*, 85, 6, 612–22.
- Guerrero-Rivera, S., Gutiérrez-Espíndola, G., Talavera, J.O., Meillón-García, L.A., Pedraza-Echevarría, M., Pizzuto-Chávez, J., 2003, Hemoglobin and platelet count effect on platelet yields in plateletpheresis, *Archives of Medical Research*, 34, 2, 120–123.

- Hagino, T., Sato, T., Tsuno, Tasaki, 2021, Incidence and management of non-immune platelet transfusion refractoriness: A narrative review, *Annals of Blood*, 6, 9.
- Heim, D., Passweg, J., Gregor, M., Buser, A., Theocharides, A., Arber, C., *et al.*, 2008, Patient and product factors affecting platelet transfusion results, *Transfusion*, 48, 881–7.
- Hughes, W.T., Armstrong, D., Bodey, G.P., Feld, R., Mandell, G.L., Meyers, J.D., *et al.*, 1990, Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever, *J Infect Disease*, 161, 3, 381–396.
- Hungria, D.M., Tietsche, V., Chiatton, C., Pavlovsky, M., Abenoza, L.M., Agreda, G.P., *et al.*, 2019, Epidemiology of hematologic malignancies in real-world settings: Findings from the hemato-oncology Latin america observational registry study, *J Glob Oncol*, 2019, 5, 1–19.
- Hutchison, R., McPherson, R., Schexneider, K., 2011, *Basic examination of blood and bone marrow. Henry's clinical diagnosis and management by laboratory methods.*, 22nd ed, Elsevier Saunders, Philadelphia.
- Jaime-Pérez, J.C., Vázquez-Hernández, K.E., Jiménez-Castillo, R.A., Fernández, L.T., Salazar-Riojas, R., Gómez-Almaguer, D., 2018, Platelet survival in hematology patients assessed by the corrected count increment and other formulas, *Am J Clin Pathol*, 150, 3, 267–272.
- Kaufman, M. & Shehata, N., 2018, *Hemotherapy Decision and Their Outcomes: AABB Technical Manual*, Chapter 19.
- Keng, M.K. & Sekeres, M.A., 2013, Febrile neutropenia in hematologic malignancies, *Curr Hematol Malig Rep*, 8, 4, 370–378.
- Keykhaei, M., Masinaei, M., Mohammadi, E., Azadnajafabad, S., Rezaei, Negar, Saeedi Moghaddam, S., *et al.*, 2021, A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017, *Exp Hematol Oncol*, 10, 1, 1–15.
- Landzo, E., Sofo-Hafizovic, A., Cetkovic-Basic, V., 2013, Initial values of donor hematocrit and efficiency of plateletpheresis, *Acta Inform Med*, 21, 2, 116–119.
- Lee, C.S., Davis, S.M., Doremus, B., Kouk, S., Stetson, W.B., 2016, Interobserver Agreement in the Classification of Partial-Thickness Rotator Cuff Tears Using the Snyder Classification System, *Orthop J Sports Med*, 4, 9, 1–5.
- Liebman, H.A., 2014, Thrombocytopenia in cancer patients, *Thromb Res*, 133, 2, S63–69.
- Lim, J.U., Lee, J.H., Kim, J.S., Hwang, Y., Kim, T.H., Lim, S.Y., *et al.*, 2017, Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients, *International Journal of COPD*, 12, 2465–2475.
- Mangwana, S., 2014, Influence of donor demographics on the platelet yield during plateletpheresis - experience of 1100 procedures at a tertiary-care hospital, *Journal of Pathology of Nepal*, 4, 7, 525–529.
- McHugh, M., 2012, Lessons in biostatistics interrater reliability : the kappa statistic, *Biochem Med*, 22, 3, 276–282.

- Mosteller, R., 1987, Simplified calculation of body-surface area, *N Engl J Med*, 317, 17, 1098.
- Muraki, R., Hiraoka, A., Nagata, K., Nakajima, K., Oshita, T., Arimichi, M., *et al.*, 2018, Novel method for estimating the total blood volume: The importance of adjustment using the ideal body weight and age for the accurate prediction of haemodilution during cardiopulmonary bypass, *Interact Cardiovasc Thorac Surg*, 27, 6, 802–807.
- Nalezinski, S., 2022, How do I Select Evidence-Based Transfusion Thresholds for Platelets, Plasma, and Cryoprecipitate?, *AABB*, 7, 1–9.
- National Blood Authority Australia, 2015, Clinical Indications for Apheresis and Whole Blood Pooled Platelets, 11, 1–16.
- Nifosi, G., 2016, Hematologic Emergencies, *Open Journal of Internal Medicine*, 06, 03, 83–92.
- Obeagu, E.I., Babar, Q., Obeagu, G.U., 2021, Allergic blood Transfusion reaction : A Review, *Int. J. Curr. Res. Med. Sci.*, 7, 5, 25–33.
- Pavenski, K., Freedman, J., Semple, J., 2012, HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management, *Tissue Antigens*, 79(4), 237–45.
- Peraturan Menteri Kesehatan Republik Indonesia, 2015, Peraturan Menteri Kesehatan Republik Indonesia Nomor 91 tahun 2015 Tentang Standar Pelayanan Transfusi Darah, 51–67.
- Perelman, I., Khair, S., Dermer, E., Tinmouth, A., Saidenberg, E., Fergusson, D., 2019, The epidemiology of multicomponent blood transfusion: a systematic review, *Transfusion Medicine*, 29, 2, 80–94.
- Pérez, G.B., Calaf, G.M., Villalba, M.T.M., Prieto, K.S., Burgos, F.C., 2019, Frequency of hematologic malignancies in the population of Arica, Chile, *Oncology Letters*, 18, 5, 5637–5643.
- Piatek, C.I. & Liebman, H.A., 2017, Thrombocytopenia in Patients with Solid Tumors or Hematologic Malignancies, *Springer International Publishing*, 841–849.
- Rajadhyaksha, B., Desai, D., Navkudkar, A., 2019, Platelet refractoriness, *Glob J Transfus Med*, 4, 140–7.
- Rebulla, P., 1993, Formulae for the definition of refractoriness to platelet transfusion, *Transfusion Medicine*, 3, 1, 91–92.
- Redlarski, G., Palkowski, A., Krawczuk, M., 2016, Body surface area formulae: An alarming ambiguity, *Sci. Rep*, 6, 1–8.
- Ricos, C., Alvarez, V., Cava, F., Garcia-Lario, J., Hernandez, A., Jimenez, C., *et al.*, 1999, Current databases on biologic variation: pros, cons and progress, *Scand J Clin Lab Invest*, 59, 491–500.
- Rodriguez-Abreu, D., Bordoni, A., Zucca, E., 2007, Epidemiology of hematological malignancies, *Ann Oncol*, 18, 1, 3–8.

- Sahoo, D., Mahapatra, S., Parida, P., Panigrahi, R., 2017, Various aspects of plateletpheresis: Its impact on donor and patients, *Global Journal of Transfusion Medicine*, 2, 2, 149.
- Saris, A., Kreuger, A.L., Brinke, A., Kerkhoffs, J.L.H., Middelburg, R.A., Zwaginga, J.J. *et al.*, 2019, The quality of platelet concentrates related to corrected count increment: linking in vitro to in vivo, *Transfusion*, 59, 2, 697–706.
- Shastry, S. & Chaudhary, R., 2012, Clinical factors influencing corrected count increment, *Transfus Apher Sci*, 47, 3, 327–330.
- Shaz, B.H., Hillyer, C.D., Roshal, M., Abrams, C.S., 2018, *Transfusion Medicine and Hemostasis Clinical and Laboratory Aspects*, 3rd ed, Elsevier, Amsterdam.
- Shehata, N., Tinmouth, A., Naglie, G., Freedman, J., Wilson, K., 2009, ABO-identical versus nonidentical platelet transfusion: A systematic review, *Transfusion*, 49, 11, 2442–2453.
- Shirazu, I., Theophilus, A., Tiburu, E., Mensah, Y., 2018, The use of Body Surface Index as a Better Clinical Health indicators Compare to Body Mass Index and Body Surface Area for Clinical Application, *Int. J. S. Res. Sci. Engg. Technol.*, 12, 131–136.
- Sim, J. & Wright, C.C., 2005, The kappa statistic in reliability studies: Use, interpretation, and sample size requirements, *Physical Therapy*, 85, 3, 257–268.
- Slichter, S.J., Davis, K., Enright, H., Braine, H., Gernsheimer, T., Kao, K.J., *et al.*, 2005, Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients, *Blood*, 105, 10, 4106–4114.
- Sood, R., Mancinetti, M., Betticher, D., Cantin, B., Ebnetter, A., 2020, Management of bleeding in palliative care patients in the general internal medicine ward: a systematic review, *Ann Med Surg*, 50, December 2019, 14–23.
- Sripati, T.K., Govindarajan, Ganapathy, H., 2020, Evaluation of Thrombocytopenia in Hematological Malignancies, *J Pharm Res Int*, 1, 12, 81–85.
- Stanworth, S.J., Navarrete, C., Estcourt, L., Marsh, J., 2015, Platelet refractoriness - practical approaches and ongoing dilemmas in patient management, *Br J Haematol*, 171, 3, 297–305.
- Suddock, J. & Crookston, K., 2022, *Transfusion Reactions*. In: *StatPearls*, Treasure Island (FL), StatPearls Publishing.
- Umashankar, T., Thomas, B.M., Sahana, P., 2014, Estimation of platelet count in unstained peripheral blood smears in comparison with stained smears and evaluation of its efficacy, *Malays J Pathol*, 36, 3, 195–199.
- Vakiti, A. & Mewawalla, P., 2021, *Acute Myeloid Leukemia*. In: *StatPearls*, Treasure Island (FL), StatPearls Publishing.
- Vasilevskyi, O.M., 2014, Calibration method to assess the accuracy of measurement devices using the theory of uncertainty, *Int. J. Metrol. Qual. Eng.*, 5, 4.
- Vis, J.Y. & Huisman, A., 2016, Verification and quality control of routine hematology analyzers, *Int Jnl Lab Hem*, 38, 5, 100–109.